Veramyst Treats Seasonal and Year-Round Allergies

Nasal spray sanctioned for people two years and older

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, April 30, 2007 (HealthDay News) -- GlaxoSmithKline's Veramyst (fluticasone furoate) has been approved by the U.S. Food and Drug Administration to treat symptoms of seasonal and perennial allergies in people two years and older, the company said Monday.

The corticosteroid spray was particularly effective in reducing itchy, water eyes, in addition to stemming typical nasal symptoms including congestion, sneezing, and itchy and runny nose, Glaxo said in news release.

The drug was evaluated in clinical trials involving more than 2,900 adults and children. The most common adverse reactions included headache, nose bleed, and nasal sores.

The prescription spray should be available nationwide in the United States by the end of May, Glaxo said.

More information

Visit this FDA page to learn more about the approval.


Last Updated: